Skip to main content
← All trials
Hereditary Angioedema (HAE)Rare diseaseDrugPhase 3

What this study is

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

What's being tested

  • ADX-324 Dose Level 1

    Intervention · DRUG

  • ADX-324 Dose Level 2

    Intervention · DRUG

Both interventions

siRNA duplex oligonucleotide

Study details

Official title
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor
ADARx Pharmaceuticals, Inc.
Conditions
Hereditary Angioedema (HAE) · Hereditary Angioedema - Type 1 · Hereditary Angioedema - Type 2 · HAE
Enrolling
90 people
Starts
2026-04-02
Est. completion
2030-06-30
Design
Double-blind, non-randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗